Selected stock price target news of the day - March 19th, 2025

By: Matthew Otto

Trevi Therapeutics Reports Clinical Data and Financial Performance for 2024

Trevi Therapeutics has announced encouraging developments in its clinical programs targeting chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The Phase 2a RIVER trial demonstrated that Haduvio™ achieved a statistically significant reduction in 24-hour cough frequency. This is with a 57% placebo-adjusted change from baseline (p<0.0001).

The Phase 2b CORAL trial completed enrollment of 160 patients in February 2025, with topline data anticipated in the second quarter of 2025. Notably, chronic cough affects up to 80% of IPF patients.

Financially, Trevi reported a net loss of $11.4 million for Q4 2024, an increase from $7.8 million in the same period of 2023. Earnings per share (EPS) of ($0.11) slightly exceeded analyst expectations of ($0.12). Research and development expenses rose to $9.3 million in Q4 2024 from $6.5 million in Q4 2023, reflecting ongoing investments in clinical trials. General and administrative expenses increased to $2.9 million from $2.4 million in the prior-year period. Trevi concluded 2024 with $107.6 million in cash, cash equivalents, and marketable securities.

Analysts Reaffirm Buy Ratings with Adjusted Price Targets

Needham analyst Serge Belanger maintained a Buy rating and lowered the price target from $25 to $24.
D. Boral Capital analyst Jason Kolbert kept a Buy rating and a $21 price target.
HC Wainwright & Co. analyst Oren Livnat reiterated a Buy rating and a $12.50 price target.
Stifel analyst Annabel Samimy reaffirmed a Buy rating and the price target at $15.00.
Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and a $29.00 price target.

Which Analyst has the best track record to show on TRVI?

Analyst Mayank Mamtani (B. RILEY) currently has the highest performing score on TRVI with 2/2 (100%) price target fulfillment ratio. His price targets carry an average of $3.12 (108.33%) potential upside. Trevi Therapeutics stock price reaches these price targets on average within 426 days.

Absci Reports 2024 Results, Highlights AI Advances and Partnerships

Absci reported its financial and operating results for the fourth quarter and full year ended December 31, 2024, highlighting advancements in its AI-driven drug discovery platform and strategic collaborations. During its 2024 R&D Day, Absci unveiled updates across its proprietary pipeline, including ABS-201 for androgenic alopecia, which affects approximately 80 million individuals in the U.S. alone, and ABS-101 for inflammatory diseases.

Absci entered into a collaboration with AMD, securing a $20 million equity investment to accelerate AI-powered drug discovery efforts. Achieved its 2024 outlook for drug creation partnerships, securing agreements with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center.

Looking ahead, Absci anticipates launching Phase 1 clinical trials for ABS-101 in the first half of 2025, with an interim data readout expected in the second half of the year. ABS-201 is expected to enter Phase 1 trials in early 2026, with the potential to provide a safer alternative to current treatments for millions of patients.

Financially, Absci reported a fourth-quarter revenue of $0.7 million, missing the consensus estimate of $1.8 million. Reported a Q4 EPS of ($0.25), falling $0.03 below analyst expectations of ($0.22).

Full-year revenue declined to $4.5 million from $5.7 million in 2023. Research and development expenses increased 33% year-over-year to $63.9 million. Selling, general, and administrative expenses declined slightly to $36.2 million from $37.8 million. Absci reduced its net loss from $110.6 million in 2023 to $103.1 million in 2024. As of December 31, 2024, Absci held $112.4 million in cash, cash equivalents, and short-term investments, a decrease from $127.1 million in the previous quarter.

Analysts Reiterate Buy Ratings Following 2024 Results

Needham analyst Gil Blum reiterated a Buy rating and a $9 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth kept a Buy rating and a $7 price target.

Which Analyst has the best track record to show on ABSI?

Analyst Scott Schoenhaus (KEYBANK) currently has the highest performing score on ABSI with 3/5 (60%) price target fulfillment ratio. Her price targets carry an average of $1.78 (55.28%) potential upside. Absci stock price reaches these price targets on average within 30 days.

Stoke Therapeutics Reports Year-End 2024 Financial Results and Business Updates

Stoke Therapeutics remains on track to initiate the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome in the second quarter of 2025. As of year-end, Stoke had $246.7 million in cash, cash equivalents, and marketable securities.

Combined with the $165 million upfront payment and additional potential proceeds from its Biogen collaboration, Stoke anticipates funding operations through mid-2028. Notable developments include the FDA granting Breakthrough Therapy Designation for zorevunersen, positive data from open-label extension studies, and regulatory alignment across the U.S., Europe, and Japan for the upcoming Phase 3 trial.

Financially, Stoke reported $36.6 million in revenue for 2024, up from $8.8 million in 2023. Stoke posted a net loss of $89.0 million ($1.65 per share), an improvement from a $104.7 million net loss ($2.38 per share) in 2023. Research and development expenses increased to $89.1 million from $82.2 million. General and administrative expenses rose to $48.8 million from $41.3 million.

In the fourth quarter of 2024, Stoke reported earnings per share (EPS) of ($0.18), exceeding analyst estimates of ($0.55) by $0.37. Quarterly revenue came in at $22.61 million, surpassing the consensus estimate of $4.1 million.

Analysts Reaffirm Buy Ratings Amid Financial Performance

HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating and a $47 price target.
Chardan Capital analyst Rudy Li maintained a Buy rating and a $24 price target.

Which Analyst has the best track record to show on STOK?

Analyst Joseph Stringer (NEEDHAM) currently has the highest performing score on STOK with 5/19 (26.32%) price target fulfillment ratio. His price targets carry an average of $11.32 (105.99%) potential downside. Stoke Therapeutics stock price reaches these price targets on average within 48 days.